Top

Published in:

Open Access 01-06-2020 | Anemia | Review Article

Management of myelofibrosis after ruxolitinib failure

Authors: Claire N Harrison, Nicolaas Schaap, Ruben A Mesa

Published in: Annals of Hematology | Issue 6/2020

Abstract

Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway, and other cellular pathways downstream, leads to myeloproliferation, proinflammatory cytokine expression, and bone marrow remodeling. Transplant is the only curative option for myelofibrosis, but high rates of morbidity and mortality limit eligibility. Several prognostic models have been developed to facilitate treatment decisions. Until the recent approval of fedratinib, a JAK2 inhibitor, ruxolitinib was the only available JAK inhibitor for treatment of intermediate- or high-risk myelofibrosis. Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitinib after 2–3 years of therapy. Currently, there is no consensus definition of ruxolitinib failure. Until fedratinib approval, strategies to overcome ruxolitinib resistance or intolerance were mainly different approaches to continued ruxolitinib therapy, including dosing modifications and ruxolitinib rechallenge. Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to induce clinical responses and improve symptoms in patients previously treated with ruxolitinib. Fedratinib induces robust spleen responses, and pacritinib and momelotinib may have preferential activity in patients with severe cytopenias. Reviewed here are strategies to ameliorate ruxolitinib resistance or intolerance, and outcomes of clinical trials in patients with myelofibrosis receiving second-line JAK inhibitors after ruxolitinib treatment.

Tefferi A (2016) Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91(12):1262–1271. https://doi.org/10.1002/ajh.24592 CrossRefPubMed

Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kroger N, Thiele J, Barbui T, Barosi G (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395–1398. https://doi.org/10.1182/blood-2013-03-488098 CrossRefPubMedPubMedCentral

Shammo JM, Stein BL (2016) Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions. Hematology Am Soc Hematol Educ Program 2016(1):552–560. https://doi.org/10.1182/asheducation-2016.1.552 CrossRefPubMedPubMedCentral

Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861–1869. https://doi.org/10.1038/leu.2013.119 CrossRefPubMed

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D’Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N (2018) Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. Semin Hematol 55(4):248–255. https://doi.org/10.1053/j.seminhematol.2018.05.013 CrossRefPubMed

de Freitas RM, da Costa Maranduba CM (2015) Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. Rev Bras Hematol Hemoter 37(5):348–353. https://doi.org/10.1016/j.bjhh.2014.10.001 CrossRefPubMedPubMedCentral

O’Sullivan JM, Harrison CN (2018) Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 16(2):121–131PubMed

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. https://doi.org/10.1182/blood-2008-07-170449 CrossRefPubMed

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708. https://doi.org/10.1182/blood-2009-09-245837 CrossRefPubMed

10.

Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392–397. https://doi.org/10.1200/JCO.2010.32.2446 CrossRefPubMed

11.

Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16(3):358–367. https://doi.org/10.1016/j.bbmt.2009.10.025 CrossRefPubMed

12.

Devlin R, Gupta V (2016) Myelofibrosis: to transplant or not to transplant? Hematology Am Soc Hematol Educ Program 2016(1):543–551. https://doi.org/10.1182/asheducation-2016.1.543 CrossRefPubMedPubMedCentral

13.

Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F (2015) Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 125(21):3347–3350; quiz 3364. https://doi.org/10.1182/blood-2014-10-608315 CrossRefPubMedPubMedCentral

14.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A (2018) MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36(4):310–318. https://doi.org/10.1200/JCO.2017.76.4886 CrossRefPubMed

15.

Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM (2018) Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol 93(3):348–355. https://doi.org/10.1002/ajh.24978 CrossRefPubMed

16.

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM (2018) MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 36(17):1769–1770. https://doi.org/10.1200/JCO.2018.78.9867 CrossRefPubMed

17.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema G, Pardanani A, Vannucchi AM (2018) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32(7):1631–1642. https://doi.org/10.1038/s41375-018-0107-z CrossRefPubMedPubMedCentral

18.

Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socie G, Beelen D, Triviai I, Badbaran A, Kroger N (2019) Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 133(20):2233–2242. https://doi.org/10.1182/blood-2018-12-890889 CrossRefPubMed

19.

Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV (2013) Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 4(1):15–35. https://doi.org/10.1177/2040620712461047 CrossRefPubMedPubMedCentral

20.

Pardanani A, Tefferi A (2014) Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J 4:e268. https://doi.org/10.1038/bcj.2014.84 CrossRefPubMedPubMedCentral

21.

Passamonti F, Maffioli M (2018) The role of JAK2 inhibitors in MPNs 7 years after approval. Blood 131(22):2426–2435. https://doi.org/10.1182/blood-2018-01-791491 CrossRefPubMed

22.

Jakafi^® (ruxolitinib) prescribing information. Incyte Corporation, Wilmington, DE. Rev 05/2019. Available at: https://www.jakafi.com/pdf/prescribing-information.pdf. Accessed June 19, 2018

23.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798. https://doi.org/10.1056/NEJMoa1110556 CrossRefPubMed

24.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807. https://doi.org/10.1056/NEJMoa1110557 CrossRefPubMedPubMedCentral

25.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701–1707. https://doi.org/10.1038/leu.2016.148 CrossRefPubMedPubMedCentral

26.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, investigators C-I (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https://doi.org/10.1186/s13045-017-0417-z CrossRefPubMedPubMedCentral

27.

Palandri F, Elli EM, Polverelli N, Bonifacio M, Benevolo G, Abruzzese E, Bergamaschi M, Tieghi A, Iurlo A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Latagliata R, Auteri G, Scaffidi L, Cattaneo D, Catani L, Krampera M, Vitolo U, Aversa F, Lemoli RM, Cuneo A, Semenzato G, Foa R, Di Raimondo F, Cavo M, Bartoletti D, Vianelli N, Breccia M, Palumbo GA (2018) Outcome of patients with myelofibrosis after ruxolitinib failure: role of disease status and treatment strategies in 214 patients. Blood 132(Suppl 1):abstract 4277CrossRef

28.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97(3):435–441. https://doi.org/10.1007/s00277-017-3194-4 CrossRefPubMed

29.

Fonseca E, Silver RT, Kazis LE, Iqbal SU, Rose M, Khan N (2013) Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice. Blood 122:abstract 2833CrossRef

30.

Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S (2017) Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125–1131. https://doi.org/10.1182/blood-2017-05-783225 CrossRefPubMedPubMedCentral

31.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V (2016) Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant 22(3):432–440. https://doi.org/10.1016/j.bbmt.2015.10.005 CrossRefPubMed

32.

INREBIC^® (fedratinib) prescribing information. Impact Biomedicines, Inc., Summit, NJ; Rev 08/2019

33.

Kvasnicka HM (2017) How to define treatment failure for JAK inhibitors. Lancet Haematol 4(7):e305–e306. https://doi.org/10.1016/S2352-3026(17)30102-3 CrossRefPubMed

34.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, W inton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA (2017) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4(7):e317–e324. https://doi.org/10.1016/s2352-3026(17)30088-1 CrossRefPubMed

35.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73–e81. https://doi.org/10.1016/S2352-3026(17)30237-5 CrossRefPubMed

36.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S (2018) Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 4(5):652–659. https://doi.org/10.1001/jamaoncol.2017.5818 CrossRefPubMed

37.

Harrison CN, Schaap N, Vannucchi AM, Kiladijan JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA (2020) Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. https://doi.org/10.1002/ajh.25777

38.

Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O’Neill C, Sekeres M, O’Connell C (2018) Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: a case series. Clin Lymphoma Myeloma Leuk 18(11):e463–e468. https://doi.org/10.1016/j.clml.2018.06.025 CrossRefPubMed

39.

Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643–651. https://doi.org/10.1001/jamaoncol.2015.1590 CrossRefPubMed

40.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844–3850. https://doi.org/10.1200/JCO.2017.73.4418 CrossRefPubMedPubMedCentral

41.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN (2017) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 4(5):e225–e236. https://doi.org/10.1016/S2352-3026(17)30027-3 CrossRefPubMed

42.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, Investigators C (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100(9):1139–1145. https://doi.org/10.3324/haematol.2014.119545 CrossRefPubMedPubMedCentral

43.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN (2014) Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology guidelines for investigation and management of myelofibrosis 2012. Br J Haematol 167(3):418–420. https://doi.org/10.1111/bjh.12985 CrossRefPubMed

44.

National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology—myeloproliferative neoplasms v3.2020

45.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D’Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, De Marchi EC, Anaclerico B, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Cavo M, Vianelli N, Breccia M (2016) Predictors for response to ruxolitinib in real-life: an observational independent study on 408 patients with myelofibrosis. Blood 128:abstract 1128CrossRef

46.

Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S (2015) Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790–797. https://doi.org/10.1182/blood-2015-03-633404 CrossRefPubMedPubMedCentral

47.

Talpaz M, Erickson-Viitanen S, Hou K, Hamburg S, Baer MR (2018) Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. J Hematol Oncol 11(1):101. https://doi.org/10.1186/s13045-018-0642-0 CrossRefPubMedPubMedCentral

48.

Pardanani A, Tefferi A (2018) How I treat myelofibrosis after failure of JAK inhibitors. Blood 132(5):492–500. https://doi.org/10.1182/blood-2018-02-785923 CrossRefPubMed

49.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, investigators C-I (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479–488. https://doi.org/10.3324/haematol.2014.115840 CrossRefPubMedPubMedCentral

50.

Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, investigators C-I (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047–4053. https://doi.org/10.1182/blood-2013-02-485888 CrossRefPubMed

51.

Meyer SC, Levine RL (2014) Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 20(8):2051–2059. https://doi.org/10.1158/1078-0432.CCR-13-0279 CrossRefPubMedPubMedCentral

52.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL (2012) Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489(7414):155–159. https://doi.org/10.1038/nature11303 CrossRefPubMedPubMedCentral

53.

Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95(1):19–29CrossRefPubMed

54.

Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K (2017) Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol 105(3):309–317. https://doi.org/10.1007/s12185-016-2130-z CrossRefPubMed

55.

Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C (2015) Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol 170(1):29–39. https://doi.org/10.1111/bjh.13379 CrossRefPubMed

56.

Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villiva N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R (2017) Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol 96(3):387–391. https://doi.org/10.1007/s00277-016-2884-7 CrossRefPubMed

57.

Al-Ali HK, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, Le Coutre P, Garcia-Hernandez C, Zaritskey A, Tavares R, Griesshammer M, Gupta V, Raanani P, Giraldo P, Bouard C, Ronco JP, Tiwari R, Mannelli F, Vannucchi AM (2017) Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 2233). Blood 130:Abstract 4204

58.

Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101(9):1065–1073. https://doi.org/10.3324/haematol.2016.143677 CrossRefPubMedPubMedCentral

59.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13–21. https://doi.org/10.2147/OTT.S53348 CrossRefPubMedPubMedCentral

60.

Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O’Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6(1):81. https://doi.org/10.1186/1756-8722-6-81 CrossRefPubMedPubMedCentral

61.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117–1127. https://doi.org/10.1056/NEJMoa1002028 CrossRefPubMedPubMedCentral

62.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H (2019) EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica 104(5):947–954. https://doi.org/10.3324/haematol.2018.204602 CrossRefPubMedPubMedCentral

63.

Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86(12):1188–1191. https://doi.org/10.4065/mcp.2011.0518 CrossRefPubMedPubMedCentral

64.

Dai T, Friedman EW, Barta SK (2013) Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 31(29):e430–e432. https://doi.org/10.1200/jco.2012.47.6473 CrossRefPubMed

65.

Beauverd Y, Samii K (2014) Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol 100(5):498–501. https://doi.org/10.1007/s12185-014-1628-5 CrossRefPubMedPubMedCentral

66.

Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM (2017) A life-threatening ruxolitinib discontinuation syndrome. Am J Hematol 92(8):833–838. https://doi.org/10.1002/ajh.24775 CrossRefPubMed

67.

Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13(4):311–320. https://doi.org/10.1016/j.ccr.2008.02.009 CrossRefPubMed

68.

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research 7:82. https://doi.org/10.12688/f1000research.13167.1 CrossRefPubMedPubMedCentral

69.

Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51(12):1644–1654. https://doi.org/10.1177/0091270010389469 CrossRefPubMed

70.

Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33(9):1199–1203. https://doi.org/10.1016/j.leukres.2009.01.035 CrossRefPubMedPubMedCentral

71.

Harrison C, Schaap N, Vannucchi A, Kiladijan JJ, Jourdan E, Silver R, Schouten H, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Gerike T, Rose S, Li M, Berry T, Brownstein C, Mesa R (2019) Fedratinib induces spleen responses in patients with myeloproliferative neoplasm (MPN)-associated intermediate- or high-risk myelofibrosis (MF) resistant or intolerant to ruxolitinib: an updated analysis of the phase II JAKARTA2 study. Clin Lymphoma Myeloma Leuk 19(Suppl 1):S356CrossRef

72.

Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5:e335. https://doi.org/10.1038/bcj.2015.63 CrossRefPubMedPubMedCentral

73.

Ogershok PR, Rahman A, Nestor S, Brick J (2002) Wernicke encephalopathy in nonalcoholic patients. Am J Med Sci 323(2):107–111CrossRefPubMed

74.

Curto-Garcia N, Harrison CN, McLornan DP, Radia DH (2017) Thiamine deficiency appears uncommon in patients with myeloproliferative neoplasms. Br J Haematol 178(2):338–340. https://doi.org/10.1111/bjh.14128 CrossRefPubMed

75.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789–796. https://doi.org/10.1200/JCO.2010.32.8021 CrossRefPubMedPubMedCentral

76.

Gotlib J, Pardanani A, Jamieson C, Cortes J, Talpaz M, Stone R, Gao G, Zhang J, Neumann F, Lebedinsky C, Tefferi A (2012) Long-term follow up of a phase 1/2 study of SAR302503, an oral JAK2 selective inhibitor, in patients with myelofibrosis (MF). Haematologica 97(s1):abstract 0361

77.

Hart S, Goh KC, Novotny-Diermayr V, Tan YC, Madan B, Amalini C, Ong LC, Kheng B, Cheong A, Zhou J, Chng WJ, Wood JM (2011) Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J 1(11):e44. https://doi.org/10.1038/bcj.2011.43 CrossRefPubMedPubMedCentral

78.

Gerds AT, Savona MR, SCott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi AM, Mead AJ, O’Sullivan J, Buckley SA, Mould DR, Tyavanagimatt S, Smith JA, Mascarenhas J (2019) Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib. Blood 134(S1):abstract 667CrossRef

79.

Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87(1):25–33. https://doi.org/10.1016/j.mayocp.2011.11.001 CrossRefPubMedPubMedCentral

80.

Mesa RA, Talpaz M, Kiladjian JJ, Harrison CN, Verstovsek S, Buckley SA, Roman-Torres K, Mascarenhas J (2019) Pacritinib demonstrates efficacy versus best available therapy in myelofibrosis patients with severe thrombocytopenia in two phase 3 studies. Blood 134(s1):abstract 634

81.

Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, Seifert M, Posch W, Nairz M, Maciejewski P, Fowles P, Burns CJ, Smith G, Wagner KU, Weiss G, Whitney JA, Theurl I (2017) Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 129(13):1823–1830. https://doi.org/10.1182/blood-2016-09-740092 CrossRefPubMedPubMedCentral

82.

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A (2018) Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia 32(4):1035–1038. https://doi.org/10.1038/leu.2017.330 CrossRefPubMed

83.

Pettit K, Odenike O (2017) Novel therapies for myelofibrosis. Curr Hematol Malig Rep 12(6):611–624. https://doi.org/10.1007/s11899-017-0403-0 CrossRefPubMedPubMedCentral

Title: Management of myelofibrosis after ruxolitinib failure
Authors: Claire N Harrison
Nicolaas Schaap
Ruben A Mesa
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Anemia
Ruxolitinib
Published in: Annals of Hematology / Issue 6/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04002-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy

Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion

Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials

Red blood cell consumption in a large cohort of patients with thalassaemia: a retrospective analysis of main predictors

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage